Surface Oncology

SRF373 / NZV930 CD73 Antibody

CD73 is an ectoenzyme that plays a key role in the generation of extracellular adenosine, a critical modulator of immune response. Inhibition of CD73 reduces levels of immunosuppressive adenosine in the tumor microenvironment allowing key immune cells, including T cells, to attack the tumor.

SRF373 / NZV930
Surface has developed a fully human CD73 antibody, SRF373 also known as NZV930, which has been shown in non-clinical studies to inhibit CD73 enzymatic activity, reduce levels of adenosine, and increase the proliferation of T cell receptor-stimulated CD4+ T cells. Additionally, we have seen compelling preclinical anti-tumor activity when combining a CD73 inhibitor with a PD-1 inhibitor.

We have granted Novartis worldwide development and commercialization rights to SRF373 and a Phase I clinical trial was initiated in June 2018.